

09/868779

JC18 Rec'd PCT/PTO 21 JUN 2001

PATENT  
3813-0101P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: TESHIGAWARA, Keisuke et al. Conf.:  
Appl. No.: New Group:  
Filed: June 21, 2001 Examiner:  
For: METHOD FOR IN VITRO CULTURE OF  
LYMPHOCYTES AND COMPOSITION FOR USE IN  
IMMUNE THERAPY

INFORMATION DISCLOSURE STATEMENT  
(SUBMISSION CONCURRENT WITH THE  
FILING OF A NEW PATENT APPLICATION)

Assistant Commissioner for Patents  
Washington, DC 20231

June 21, 2001

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II. COPIES

- ☐ Submitted herewith is a legible copy of (i) each U.S. and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.
- ☒ This application is a National Phase of a PCT application. Some or all of the documents listed on the PTO-1449 are not enclosed because they were cited in the International Search Report and copies should be forwarded from the International Search Authority. If copies are needed, please contact the undersigned.

III. CONCISE EXPLANATION OF THE RELEVANCE  
(check at least one box)

a. ☐ **DOCUMENTS IN THE ENGLISH LANGUAGE**

The attached patents, publications, or other information in the English language do not require a statement of relevancy.

b. ☐ **DOCUMENTS NOT IN THE ENGLISH LANGUAGE**

A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

c. ☒ **ENGLISH LANGUAGE SEARCH REPORT**

An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(A)(3).

d. ☐ **OTHER**

The following additional information is provided for the Examiner's consideration.

09/868779

Rec'd PCT/PTO 21 JUN 2001  
Docket No. 3813-0101P

FEES

This Information Disclosure Statement is being filed concurrently with the filing of a new patent application; therefore, no fee is required.

If The Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 

Raymond C. Stewart, #21,066

RCS/cqc  
3813-0101P

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

Enclosures: ☒ Form PTO-1449(s)  
☐ Documents  
☐ Foreign Search Report  
☐ Fee  
☒ Other: International Search Report

(Rev. 01/22/01)

09/868779

U.S. Patent PCT/PTO 21 JUN 2001

Form PTO-1449

**INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION**

Use several sheets if necessary

APP. NUMBER NO.  
3813-0101PAPPLICATION NO.  
NewAPPLICANT  
TESHIGAWARA et al.FILING DATE  
June 21, 2001

CLASS NO.

GROUP

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APP. PRIOR

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
												YES	NO
	A2000	2	4	5	4	5	1	2000-09-12	JP				
	A2	6	9	0	1	2	5	1996-01-03	EP				

**OTHER DOCUMENTS**

(Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)

		Martin-Fontecha et al., The Journal of Immunology, Vol. 162, No. 10, pp. 5910-16 (1999)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial of citation considered, whether or not citation is in compliance with MPEP, 609. Draw line through citation if not in compliance and not considered. Include copy of this form with next communication to applicant.

RCS/cgc